The T1D Fund is ushering in a new era with a leadership change that’s set to energize its mission to combat type 1 diabetes.
Come August 2025, Dr. Lucio Iannone will officially take the reins as the Fund’s new Managing Director, bringing with him an impressive blend of scientific insight and investment expertise.
Lucio Iannone Brings a Global Investment Background
Dr. Iannone isn’t new to groundbreaking health ventures.
Before stepping into this new role, he served as Head of Health Investments, USA for Leaps by Bayer, the innovation-driven investment branch of pharmaceutical giant Bayer AG.
There, he was at the forefront of steering strategic health investments, overseeing a portfolio of more than 25 biomedical projects.
His leadership extended to managing assets that totaled over $1 billion, covering areas like oncology, autoimmune disorders, cell and gene therapies, and chronic illnesses.
His deep involvement in both scientific and commercial aspects of biomedicine gives him a well-rounded perspective—an asset that aligns seamlessly with the T1D Fund’s commitment to advancing treatments and finding a cure for type 1 diabetes.
A Strong Scientific and Strategic Voice
Iannone’s academic roots trace back to Imperial College London, where he earned a Ph.D. in Medicine.
Throughout his career, he’s held board positions in several cutting-edge biotech companies, including Mozart Therapeutics, eGenesis Biosciences, and Immunitas Therapeutics, among others.
His track record reflects not just leadership, but a hands-on approach to guiding innovation from lab to market.
The T1D Fund’s Bold Mission
Founded in 2016, the T1D Fund has a clear and ambitious goal: to drive the development of therapies that can transform, prevent, or even cure type 1 diabetes.
As a venture philanthropy fund, it backs early-stage companies working on breakthrough treatments by providing equity investments and partnering with biopharma and venture capital firms.
Its work extends beyond just funding—it’s about strategically accelerating real, lasting change in the lives of those affected by T1D.
Backed by Leading Forces in Diabetes Innovation
The T1D Fund operates with the backing of two powerhouse organizations: Breakthrough T1D (formerly known as JDRF) and The Leona M. and Harry B. Helmsley Charitable Trust.
These partners are deeply committed to supporting the diabetes community and pushing the boundaries of what’s possible in medical research and innovation.
What’s on the Horizon?
With Dr. Iannone stepping into a leadership role, expectations are high for what’s next at the T1D Fund.
His experience, vision, and strategic mindset could be just what the organization needs to accelerate its impact—and bring the world one step closer to a future free from type 1 diabetes.